SCHEMBL2083370

SCHEMBL2083370

CCCCCNC(=O)N(C)c1cccc(-c2ccc(CCC(=O)OC)cc2NCc2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.41
HPGD P15428 1/20 0.39
FFAR1 O14842 3/20 0.37
FAAH O00519 1/20 0.37
PTGS2 P35354 1/20 0.37
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA3 P07451 2/20 0.36
CA6 P23280 2/20 0.36
CA5A P35218 2/20 0.36
CA7 P43166 2/20 0.36
CA13 Q8N1Q1 2/20 0.36
CA14 Q9ULX7 2/20 0.36
PLK1 P53350 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.36
CA9 Q16790 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
HDAC11 Q96DB2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2085249 0.99 PTPN1 (0.41) PTPN1HPGDFFAR1FAAHPTGS2
SCHEMBL2084180 0.94 CNR2 (0.40) PTPN1HPGDFAAHPTGS2CA12
SCHEMBL2083901 0.93 CNR2 (0.39) PTPN1HPGDFAAHPTGS2CA12
SCHEMBL12935169 0.93 FFAR1 (0.45) HPGDFFAR1FAAHPTGS2CA12
Hydrochloric Acid SCHEMBL2085510 0.92 FFAR1 (0.44) PTPN1HPGDFFAR1FAAHPTGS2
SCHEMBL12935191 0.92 FFAR1 (0.44) HPGDFFAR1FAAHPTGS2CA12
SCHEMBL2083265 0.92 PTPN1 (0.39) PTPN1HPGDFAAHPTGS2LTB4R2
SCHEMBL2084596 0.92 PTPN1 (0.39) PTPN1HPGDFAAHPTGS2LTB4R2
Hydrochloric Acid SCHEMBL2085709 0.91 FFAR1 (0.43) HPGDFFAR1FAAHPTGS2CA12
SCHEMBL2087160 0.91 PTPN1 (0.39) PTPN1HPGDFAAHPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863332-B2 Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-04 US disclosed
EP-1781297-B1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-10-15 EP disclosed
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-13 US disclosed
EP-1781297-A1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP disclosed
WO-2006018326-A1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD PTPN1 1201/4885HPGD 514/4885FFAR1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.